Visx Eyes Expanded CustomVue Indications, Readies U.S. Presbyopia Trial
This article was originally published in The Gray Sheet
Executive Summary
Visx is counting on expanded hyperopia and myopia claims to its CustomVue wavefront ablation system to spur 8%-10% sales growth in 2005
You may also be interested in...
Visx CustomVue approved for hyperopia
Vision correction system is the first wavefront-guided laser cleared by FDA for hyperopia with or without astigmatism, Visx says. The expanded indication increases the percentage of the 50 mil.-60 mil. people eligible for LASIK from 75% to 90%. CustomVue previously was approved for low-to-moderate myopia and astigmatism; studies are underway for expanded myopia treatment (1"The Gray Sheet" Nov. 1, 2004, p. 22)...
Visx CustomVue approved for hyperopia
Vision correction system is the first wavefront-guided laser cleared by FDA for hyperopia with or without astigmatism, Visx says. The expanded indication increases the percentage of the 50 mil.-60 mil. people eligible for LASIK from 75% to 90%. CustomVue previously was approved for low-to-moderate myopia and astigmatism; studies are underway for expanded myopia treatment (1"The Gray Sheet" Nov. 1, 2004, p. 22)...
AMO To Surround Eye Surgeons With Refractive Offerings After Visx Purchase
Advanced Medical Optics' acquisition of pure-play LASIK manufacturer Visx will enable the combined entity to more effectively market laser eye surgery to physicians performing both refractive and cataract procedures
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: